0
Corrections |

Clozapine Treatment for Suicidality in Schizophrenia—Correction FREE

Arch Gen Psychiatry. 2003;60(7):735. doi:10.1001/archpsyc.60.7.735.
Text Size: A A A
Published online

Errors in Text and Table. In the Original Article by Meltzer et al titled “Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT),” published in the January issue of the ARCHIVES (2003;60:82-91), the following errors occurred in the text and in a table: On page 83, right column, last paragraph, the first sentence should have read as follows: “Every potential type 1 end point (see the ‘Outcome Definitions’ subsection) was reviewed by all of the members of the SMB, and consensus was obtained.” On page 84, right column, last paragraph, the second sentence (continuing to page 85) should have read as follows: “Putative explanatory variables, that is, factors that may have contributed to the primary end point in this model, included treatment, number of previous suicide attempts, active substance or alcohol abuse, pooled country, medical center, sex, and age group (18-32, 33-44, and ≥45 years) at baseline.” On page 86, in Table 4, for the sideheading “Concomitant medications” and the subheading “Antidepressants,” the number (percentage) for the clozapine group should have read “221(46.1),” and for the olanzapine group, “258 (54.1).” In that same table, for the sideheading “Concomitant medications” and the subheading “Anxiolytics/soporifics,” the number (percentage) for the clozapine group should have read “301 (62.8),” and the P value (95% confidence interval [CI] of the difference) (olanzapine minus clozapine) should have read “.03 (.01 to .13).” On page 87, left column, last paragraph, the third sentence should have read as follows: “On the other hand, when suicide attempts were rated for probability of success by the principal investigator, a ‘high probability for success’ of a completed suicide was found for 8 events in the clozapine group and 14 events in the olanzapine group.” Also on page 87, right column, second paragraph, the third and fourth sentences should have read as follows: “The time in days to observe the first 70 patients with type 1 events was 185 days for the clozapine-treated patients and 126 days for the olanzapine-treated patients. A significant reduction in the 2-year event rate at the end of the study (olanzapine, 32.2% vs clozapine, 24.0%; 95% CI of the difference, 0.02-0.14; number needed to treat, 13) and a delay in time to event were demonstrated for clozapine-treated patients.” The last sentence in that same paragraph should have read as follows: “The overall annualized rate for attempted suicides (including suicide deaths) was 7.2%, with a rate of 8.7% for olanzapine-treated patients and 5.8% for clozapine-treated patients.” On page 88, left column, second paragraph, the first and second sentences should have read as follows: “Comparison of the overall use of concomitant medications for any reason, not only suicidality, shows that antidepressants were used more frequently in patients treated with olanzapine (54.1%) than in those treated with clozapine (46.1%) (P=.01) (Table 4). Anxiolytics and soporifics were also used more frequently in patients treated with olanzapine(69.4%) than in those treated with clozapine (62.8%) (P=.03).” Also on page 88, right column, in the “Comment” section, second paragraph, the first sentence should have read as follows: “Although the total number of suicide-related deaths was greater in the clozapine-treated group, this was not significant and, as indicated already, the study was not powered to evaluate this as an end point.” Finally, on page 90, right column, second paragraph, the third sentence should have read as follows: “The InterSePT indicates that, on average, treatment of only 13 patients with clozapine rather than olanzapine will show benefit for clozapine to reduce suicidal behavior.”

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.